Clinical trial of pidotimod combined with ganciclovir for injection in the treatment of children with infectious mononucleosis
10.13699/j.cnki.1001-6821.2018.09.002
- VernacularTitle:匹多莫德联合注射用更昔洛韦治疗传染性单核细胞增多症的临床研究
- Author:
Yu-Zhuan ZHANG
1
;
Hai-Xing YOU
;
Yan LI
Author Information
1. 海口市第三人民医院儿科
- Keywords:
pidotimod;
infectious mononucleosis;
immune function;
cytokines;
myocardial enzymes
- From:
The Chinese Journal of Clinical Pharmacology
2018;34(9):1014-1017
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical effect and safety of pidotimod combined with ganciclovir for injection in the treatment of children with infectious mononucleosis.Methods Ninety-four children with infectious mononucleosis were divided into control group and treatment group,each group 49 cases.Control group was treated with ganciclovir for injection 5 mg · kg-1 +5％ glucose injection 100 mL,q12 h,intravenous drip.On the basis of control group,treatment group was treated with pidotimod oral solution 400 mg,bid,orally.All children were treated for 2 weeks.The immune function,cytokines and myocardial enzymes were measured before and after treatment,the symptoms and signs of remission were observed and recorded,the clinical efficacy and adverse drug reactions were compared in two groups.Results After treatment,the clinical efficacy in treatment group and control group were 91.49％ (43 cases /47 cases),74.47％ (35 cases/47 cases),with significant difference (P ＜0.05).After treatment,the serum CD4 ± in treatment group and control group were (34.52 ± 7.24)％ and (29.83±6.65)％,CD8± were(26.27 ±6.36)％ and(31.82 ±6.73)％,CD4±/CD8± were 1.38 ±0.40 and 0.93 ± 0.35,immunoglobulin A (IgA) were (1.21 ± 0.25) and (0.99 ± 0.23) g · L-1,immunoglobulin G (IgG) were (10.03 ± 1.50) and (8.94 ± 1.42) g · L-1,serum tumor necrosis factor-α (TNF-α) were (1.14 ± 0.52) and (1.81 ± 0.63)ng · L-1,serum interleukin-6 (IL-6) were (11.20 ± 3.56) and (14.08 ± 3.75) ng · L-1,all with significant difference (all P ＜ 0.05).The adverse drug reactions were mild nausea,vomiting and other gastrointestinal reactions in treatment group,with the incidence of 10.64％ (5 cases/47 cases).The adverse drug reactions were mild nausea,vomiting and other gastrointestinal reactions and rash in control group,with the incidence of 8.51％ (4 cases/47 cases).There was no significant difference between the two groups (P ＞ 0.05).Conclusion The clinical effect of pidotimod combined with antiviral drugs in the treatment of children with infectious mononucleosis is exact,it can improve the immune function and reduce the myocardial enzymes and inflammatory markers.
